Ā | Survivors: N 24 | Non-survivors: N 10 | p-value (absolute difference; 95% CI) |
---|---|---|---|
Male | 8 (33%) | 5 (50%) | 0.4 (-0.17;Ā -0.52 to 0.19) |
Mean age, years (range) | 47.7(3ā68) | 52 (35ā68) | 0.6 (-4.30; -14.9 to 6.32)a |
Acute leukemia | 19 (79%) | 9 (90%) | 0.41 (-0.11; -0.35 to 6.32) |
Ā -Ā Myeloid | 14 (58%) | 8 (80%) | 0.21 (-0.22; -0.53 to 0.10) |
Other hematological disease | 5 (21%) | 1 (10%) | 0.41 (-0.21; -0.53 to 0.10) |
Intensive chemotherapy | 20 (83%) | 8 (80%) | 0.58 (0.03; -0.25 to 0.32) |
Other chemotherapy | 1 (4%) | ā | 0.70 (0.04;-0.03 to 0.12) |
Allogeneic stem cell transplant | 3 (12%) | 2 (20%) | 0.46 (-0.08; -0.35 to 0.20) |
Length of neutropenia episode (mean days, range) | |||
Ā -Ā Withā<ā1000 neutrophils/mmc | 19.4 (5ā40) | 18.9 (8ā35) | 0.70 (0.50; -5.90 to 6.90)a |
Ā -Ā Withā<ā100 neutrophils/mmc | 11.2 (5ā25) | 8.3Ā (0ā17) | 0.29 (2.90; -3.29 to 9.09)a |
Onset of KPC-K.pneumoniae BSI | |||
Ā -Ā Shock | 10 (42%) | 7 (70%) | 0.12Ā (-0.28;-0.62 to 0.06) |
Ā -<ā100 neutrophils/mmc | 21 (87%) | 8 (80%) | 0.61 (0.07; -0.20 to 0.35) |
Ā -Ā KPC-K.pneumoniae BSI developing during inactive antibiotic treatmentb | 3 (12.5%) | 8 (80%) | ā<ā0.01 (-0.67;-0.95 to -0.39) |
Active initial treatment | 23 (96%) | 3 (30%) | <ā0.01 (-0.76; -1.02 to -0.50) |
Ā -Ā Combination | 20 (83%) | 2 (20%) | ā<ā0.01 (0.63; 0.34 to 0.92) |
Ā Ā Ā Ā Ā With colistin | 10 | 1 | 0.07 (0.32; 0.04 to 0.58) |
Ā Ā Ā Ā Ā With ceftazidime/avibactam | 10 | 1 | 0.07 (0.32; 0.04 to 0.58) |
Ā -Ā Ā Monotherapy | 3 (12.5%) | 1 (10%) | 0.66 (0.02; -0.20 to 0.25) |
Ā Ā Ā Ā Ā Tigecyclinec | 2 (8.5%) | 1 (10%) | 0.66 (-0.16;-0.23 to 0.20) |
Ā Ā Ā Ā Ā Ceftazidime/avibactam | 1 (4.5%) | ā | 0.70 (0.4; -0.03 to 0.12) |
Study period | |||
Ā -Ā Period 1 (March 2012āDec 2013) | 9 (37.5%) | 9 (90%) | ā<ā0.01 (āĀ 0.52; āĀ 0.79 to āĀ 0.25) |
Ā -Ā Period 2 (Jan 2017āOct 2018) | 15 (62.5%) | 1 (10%) | ā<ā0.01 (0.52; 0.25 to 0.79) |